Safety of Escitalopram During Pregnancy

Risks and Benefits Assessment

The American Academy of Pediatrics recommends that escitalopram should be continued during pregnancy at the lowest effective dose if clinically indicated, as the benefits of treating depression often outweigh potential risks to the mother-infant dyad 1, 2
Third-trimester use of escitalopram may lead to neonatal adaptation syndrome, characterized by symptoms such as crying, irritability, jitteriness, tremors, poor feeding, and sleep disturbance in newborns 1, 2, 3
Symptoms of neonatal adaptation syndrome typically appear within hours to days after birth and most resolve within 1-2 weeks 1, 3
QT prolongation is a dose-dependent concern with escitalopram, and the FDA recommends not exceeding doses of 20 mg per day in adults over 60 years 4
Untreated depression during pregnancy is associated with premature birth, decreased initiation of breastfeeding, and potential harmful effects on the mother-infant relationship 1, 2, 4

The American Academy of Pediatrics recommends using the lowest effective dose of escitalopram during pregnancy 1, 2
Arranging for early follow-up after hospital discharge for infants exposed to escitalopram is recommended to monitor for potential adverse effects 1, 2

Clinicians should be aware of the risk for neonatal adaptation syndrome and monitor newborns accordingly, particularly following third-trimester exposure 1, 2, 3
In severely affected infants, short-term pharmacological management may be required 1
For women already on escitalopram, continuation of treatment is recommended if clinically indicated, using the lowest effective dose 1, 2

The FDA pregnancy category for escitalopram is not explicitly stated, but SSRIs generally fall into category C, indicating that potential benefits may justify potential risks, as noted by the European Heart Journal 5, 6